Tumor markers for ovarian cancer: basic research and clinical applications

doi:10.3877/cma.j.issn.1674-0785.2017.18.009

Abstract

Abstract:

Ovarian cancer is one of the most common gynecological malignancies and has the highest case fatality rate among all gynecological malignancies. Tumor markers are very important for early diagnosis, curative effect monitoring, and prognosis assessment in ovarian cancer. CA125 and HE4 are the most widely used serum tumor markers in ovarian cancer, but they have some flaws. Thus, finding more sensitive and specific tumor markers is of great importance. In recent years, with the rapid development of the second generation sequencing technology, circulating tumor DNA, circulating tumor cells, and miRNA have provided a new train of thought for identifying new tumor markers for ovarian cancer.

Key words: Ovarian cancer, Tumor markers, Circulating tumor cells

Lijuan Yang, Xianghua Yin. Tumor markers for ovarian cancer: basic research and clinical applications[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(18): 2249-2252.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2017.18.009

https://zhlcyszz.cma-cmc.com.cn/EN/Y2017/V11/I18/2249

References 35

[1]	Cohen JG, White M, Cruz A, et al. In 2014, can we do better than CA125 in the early detection of ovarian cancer? [J]. World Biol Chem, 2014, 5(3): 286-300.
[2]	Zhen S, Bian LH, Chang LL, et al. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: a meta-analysis [J]. Mol Clin Oncol, 2014, 2(4): 559-566.
[3]	徐丛剑, 王宜生, 杨子健. CA125在卵巢癌诊断中的应用困境与突破 [J]. 中国实用妇科与产科杂志, 2016, 32(5): 417-421.
[4]	Yang ZJ, Zhao BB, Li L. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer [J]. J Ovarian Res, 2016, 9(1): 57.
[5]	秦雪, 刘鑫丽, 王欣. 等血清CA125变化与上皮性卵巢癌预后及复发关系研究 [J]. 中国实用妇科与产科杂志, 2016, 32(5): 473-476.
[6]	Verheijen RH, Cibnla D, Zola P, et al. Cancer antigen 125: lost to follow-up?: a European society of gynaecological oncology consensus statement [J]. Int J Gynecol Cancer, 2012, 22(1): 170-174.
[7]	谷维, 左绪磊. 人附睾蛋白4检测早期卵巢癌 [J]. 国际妇产科学杂志, 2015, 42(2): 141-144.
[8]	Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta -analysis [J]. Eur J Obstet Gynecol Reprod Biol, 2013, 167(1): 81-85.
[9]	Anita Monika Chudecka-Głaz. ROMA, an algorithm for ovarian cancer [J]. Clinica Chimica Acta, 2015, 440(2): 143-151.
[10]	Manganaro L, Michienzi S, Vinci V, et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer [J]. OncolRep, 2013, 30(5): 2481-2487.
[11]	Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer [J]. Biomed Rep, 2016, 5(1): 41-44.
[12]	Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening(UKCTOCS): a randomised controlled trial [J]. Lancet, 2016, 387(10022): 945-56.
[13]	赵冰冰, 阳志军, 王琪, 等. 多指标联合检测的液态悬浮芯片技术在卵巢恶性肿瘤诊断中的应用 [J]. 中华妇产科杂志, 2017, 52(1): 11-19
[14]	Mitchell PS, Parkin RK, Kroh EM. Circulating microRNAs as stable blood-based marker for cancer detection [J]. PNAS, 2008, 105(30): 1051-1058.
[15]	Koji Nakamura, Kenjiro Sawada, Akihiko Yoshimura, et al. Clinical relevance of circulating cell-free microRNAs in ovarian cancer [J]. Molecular Cancer 2016, 15(1): 48-57.
[16]	Ahmad Mahdian-shakib, Ruhollah Dorostkar, Mahdi Tat, et al. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer [J]. Biomedicine & Pharmacotherapy 2016, 84: 592-600.
[17]	郭凤军, 邹颖刚, 范丽梅, 等. 微小RNA-92在上皮性卵巢癌患者血清中的筛查 [J]. 中国实验诊断学, 2015, 19(9): 1478-1480.
[18]	Meng X, Joosse SA, Müller V, et al. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients [J]. Br J Cancer, 2015, 113(9): 1358-1366.
[19]	曾玉, 许鹏飞, 陈辰, 等. 外周血循环miRNA诊断卵巢癌的Meta分析 [J]. 实用肿瘤杂志, 2016, 31(1): 52-5.
[20]	Liang H, Jiang Z, Xie G, et al. Serum microRNA-145 as a novel biomarker in human ovarian cancer [J]. Tumour Biol, 2015, 36(7): 5305-5313.
[21]	Y Liu, Z Niu, X Lin, et al. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1 Cancer Gene Therapy [J]. 2017.
[22]	Kosaka N, Takeshita F, Yoshioka Y, et al. Exosomal tumor-suppressive microRNAs as novel cancer therapy: ″exocure″ is another choice for cancer treatment [J]. Adv Drug Deliv Rev, 2013, 65(3): 376-382.
[23]	Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer [J]. Gynecol Oncol, 2008, 110(1): 13-21.
[24]	Meng X, Müller V, Milde-Langosch K, et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer [J]. Oncotarget, 2016, 7(13): 16923-16935.
[25]	Xu YZ, Xi QH, Ge WL, et al. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer [J]. Asian Pac J Cancer Prev, 2013, 14(2): 1057-1060.
[26]	zhou Q, Li W, Leng B, et al. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis [J]. PLoS One, 2016, 11(6): e0155495.
[27]	Kamat AA, Baldwin M, Urbauer D, et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker [J]. Cancer 2010, 116(8): 1918-25.
[28]	Liggett TE, Melnikov A, Yi Q, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors [J]. Gynecol Oncol, 2011, 120(1): 113-20.
[29]	Coley HM, Hatzimichael E, Blagden S, et al. Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer [J]. Oncotarget, 2012, 3(1): 78-83.
[30]	Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA [J]. Sci Transl Med, 2012, 4(136): 136-68.
[31]	Blass C, Kuhlmann JD, Webers A, et al. Gene expression profiling of single circulating tumor cells in ovarian cancer e Establishment of a multi-marker gene panel [J]. Molecular Oncology, 2016, 10(7): 1030-1042.
[32]	Michael LP, Zhao Q, Yang J, et al. Prognostic analysis of invasive circulating tumor cells(iCTCs) in epithelial ovarian cancer [J]. Gynecol Oncol, 2014, 134(3): 581-590.
[33]	Michael LP, Dong H, Tulley S, et al. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells(iCTCs) [J]. Gynecologic Oncology 2015, 137(2): 229-238.
[34]	Zhou YL, Bian BX, Yuan XL, et al. Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis [J]. PLoS One, 2015, 10(6): e0130873.
[35]	Aktas B, Kasimir-Bauer S, Heubner M, et al. Molecular profiling and prognostic relevance of circulating tumor cell in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapys [J]. 1nt J GynecolCancer, 2011, 21(5): 822-830.

Please choose a citation manager

Content to export